Immunic, Inc.
IMUX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $80 | $83 | $71 | $61 |
| G&A Expenses | $18 | $16 | $15 | $13 |
| SG&A Expenses | $18 | $16 | $15 | $13 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $33 | $17 |
| Operating Expenses | $98 | $99 | $119 | $92 |
| Operating Income | -$98 | -$99 | -$119 | -$92 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | -$2 | $6 | -$1 | -$1 |
| Pre-Tax Income | -$101 | -$94 | -$120 | -$93 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$101 | -$94 | -$120 | -$93 |
| % Margin | – | – | – | – |
| EPS | -1 | -2.11 | -3.78 | -3.92 |
| % Growth | 52.6% | 44.2% | 3.6% | – |
| EPS Diluted | -1 | -2.11 | -3.78 | -3.92 |
| Weighted Avg Shares Out | 100 | 44 | 32 | 24 |
| Weighted Avg Shares Out Dil | 100 | 44 | 32 | 24 |
| Supplemental Information | – | – | – | – |
| Interest Income | $3 | $3 | $1 | $0 |
| Interest Expense | $0 | $0 | $1 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$98 | -$99 | -$86 | -$92 |
| % Margin | – | – | – | – |